Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular stratification in clinical practice.